logo-loader
RNS
viewMidatech Pharma PLC

Form 8.3 - Midatech Pharma plc

--(BUSINESS WIRE)--LONDON 

FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY

A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

Rule 8.3 of the Takeover Code (the “Code”)

1. KEY INFORMATION

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b) Rights to subscribe for new securities (including directors’ and other employee options)

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a) Purchases and sales

(b) Cash-settled derivative transactions

(c) Stock-settled derivative transactions (including options)

(i) Writing, selling, purchasing or varying

(ii) Exercise

(d) Other dealings (including subscribing for new securities)

4. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

(b) Agreements, arrangements or understandings relating to options or derivatives

(c) Attachments

Public disclosures under Rule 8 of the Code must be made to a .Regulatory Information Service

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129.

*If the discloser is a natural person, a telephone number does not need to be included, provided contact information has been provided to the Panel’s Market Surveillance Unit.

The Code can be viewed on the Panel’s website atwww.thetakeoverpanel.org.uk.

Iroquois Capital Management, LLC

Source:Iroquois Capital Management, LLC

(a) Full name of discloser:

Iroquois Capital Management, LLC

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and

beneficiaries must be named.

 

(c) of offeror/offeree in relation to whose relevant securities this form relates:Name

Use a separate form for each offeror/offeree

 

Midatech Pharma plc

(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:

 

(e) Date position held/dealing undertaken:

For an opening position disclosure, state the latest practicable date prior to the disclosure

 

May 18, 2020

(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state “N/A”

 

 

NO

Class of relevant security:

ADR ICON US 59564R3021

 

Interests

Short positions

Number

%

Number

%

11(1) Relevant securities owned

(5and/or controlled:

11,180 ADRS

(55,900 common shares)

.001

 

 

(2) Cash-settled derivatives:

 

 

 

 

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

 

 

 

 

 

TOTAL:

11,180 ADRS

(55,900 common shares)

.001

 

 

Class of relevant security in relation to which subscription right exists:

warrant to subscribe for ordinary shares

Details, including nature of the rights concerned and relevant percentages:

136,364 at$2.05

Class of relevant security

Purchase/sale

Number of securities

Price per unit

ADR

sale

125,184

$1.57

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a

long/short position

Number of reference securities

Price per unit

 

 

 

 

 

Class of relevant security

Product description

e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which

option relates

Exercise price per unit

Type

e.g.

American, European etc.

Expiry date

Option money paid/ received per unit

 

 

 

 

 

 

 

 

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

 

 

 

 

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

ADR

 

Receipt of Placement of ADR's

136,364

$1.65

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”

 

none

 

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state “none”

 

None

 

Is a Supplemental Form 8 (Open Positions) attached?

NO

Date of disclosure:

23/06/20

Contact name:

Kimberly Page

Telephone number*:

212-974-3070

Quick facts: Midatech Pharma PLC

Price: 43.6

Market: AIM
Market Cap: £26.4 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE